BIOMARKERS FOR ALZHEIMER´S DISEASE DRUG DEVELOPMENT

BIOMARKERS FOR ALZHEIMER´S DISEASE DRUG DEVELOPMENT

Editorial:
HUMANA PRESS
Año de edición:
Materia
Farmacia
ISBN:
978-1-4939-7703-1
Páginas:
372
N. de edición:
1
Idioma:
Español
Ilustraciones:
54
Disponibilidad:
Disponible en 2-3 semanas

Descuento:

-5%

Antes:

114,40 €

Despues:

108,68 €

1. Epidemiology of Dementia: The Burden on Society, the Challenges for Research
2. Population-Based Approaches to Alzheimer’s Disease Prevention
3. Systems Biology Methods for Alzheimer’s Disease Research Toward Molecular Signatures, Subtypes, and Stages and Precision Medicine: Application in Cohort Studies and Trials
4. CSF Lipidomics Analysis: High-Resolution Mass Spectrometry Analytical Platform
5. CSF N-Glycomics Using MALDI MS Techniques in Alzheimer’s Disease
6. MicroRNA Profiling of Alzheimer’s Disease Cerebrospinal Fluid
7. Validation of a Chemiluminescence Immunoassay for Measuring Amyloid-ß in Human Blood Plasma
8. Mass Spectrometry-Based Metabolomic Multiplatform for Alzheimer’s Disease Research
9. Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases
10. Functional Magnetic Resonance Imaging in Alzheimer’ Disease Drug Development
11. Neuroimaging Methods for MRI Analysis in CSF Biomarkers Studies
12. Hybrid PET-MRI in Alzheimer’s Disease Research
13. Amyloid PET Imaging: Standardization and Integration with Other Alzheimer’s Disease Biomarkers
14. The Use of 18F-FDG PET in the Diagnostic Workup of Alzheimer’s Dementia
15. Quantification of Tau Load in Alzheimer’s Disease Clinical Trials Using Positron Emission Tomography
16. Imaging Neuroinflammation: Quantification of Astrocytosis in a Multitracer PET Approach
17. Unbiased Lipidomics and Metabolomics of Human Brain Samples
18. Neuropathological Assessment as an Endpoint in Clinical Trial Design
19. Analysis of Micro-RNA Expression by qPCR on a Microfluidics Platform for Alzheimer’s Disease Biomarker Discovery
20. Telomere Length Shortening in Alzheimer’s Disease: Procedures for a Causal Investigation Using Single Nucleotide Polymorphisms in a Mendelian Randomization Study
21. Quantifying miRNA Deregulation in Alzheimer’s Disease
22. Imaging of Microglial Activation in Alzheimer’s Disease by [11C]PBR28 PET
23. In Vivo Two-Photon Calcium Imaging of Hippocampal Neurons in Alzheimer Mouse Models
24. Cognitive Assessment in Alzheimer’s Disease Clinical Trials
25. Data Mining and Machine Learning Methods for Dementia Research

This volume aims to build a new generation of experts with a broader understanding of key topics in the Alzheimer’s disease field. Chapters guide readers through innovative approaches to the discovery of novel biomarkers in cerebrospinal fluid, innovation in blood-based biomarkers, a comprehensive overview of magnetic resonance imaging and molecular imaging approaches and their value for developing drugs for Alzheimer’s disease, cutting-edge developments in neuropathology and their relevance for Alzheimer’s disease trials, novel genomic strategies for biomarker development, and related topics including neuropsychological testing and advanced analytical methods.Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls.

Authoritative and cutting-edge, Biomarkers for Alzheimer's Disease Drug Development aims to ensure successful results in the further study of this vital field.

Features
• Includes cutting-edge methods and protocols
• Provides step-by-step detail essential for reproducible results
• Contains key notes and implementation advice from the experts